SYNAGEVA BIOPHARMA CORP - FORM 8-K - EX-16.1 - LETTER FROM ERNST & YOUNG LLP TO THE U.S. SECURITIES - November 10, 2011

Attached files

file filename
8-K - FORM 8-K - SYNAGEVA BIOPHARMA CORPd254433d8k.htm
EX-10.3 - EMPLOYMENT AGREEMENT, EFFECTIVE AS OF NOVEMBER 2, 2011 - SYNAGEVA BIOPHARMA CORPd254433dex103.htm
EX-10.5 - EMPLOYMENT AGREEMENT, EFFECTIVE AS OF NOVEMBER 2, 2011 - SYNAGEVA BIOPHARMA CORPd254433dex105.htm
EX-10.4 - EMPLOYMENT AGREEMENT, EFFECTIVE AS OF NOVEMBER 2, 2011 - SYNAGEVA BIOPHARMA CORPd254433dex104.htm
EX-10.2 - EMPLOYMENT AGREEMENT, EFFECTIVE AS OF NOVEMBER 2, 2011 - SYNAGEVA BIOPHARMA CORPd254433dex102.htm
EX-10.1 - EMPLOYMENT AGREEMENT, EFFECTIVE AS OF NOVEMBER 2, 2011 - SYNAGEVA BIOPHARMA CORPd254433dex101.htm

Exhibit 16.1

November 10, 2011

Office of the Chief Accountant

Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549-7561

Dear Sir, Madam:

We have read Item 4.01 of Form 8-K dated November 10, 2011, of Synageva Biopharma Corp. (formerly known as Trimeris, Inc.) and are in agreement with the statements contained in the second through fifth paragraphs under the heading “Prior Independent Registered Public Accounting Firm” on page two therein. We have no basis to agree or disagree with other statements of the registrant contained therein.

Very truly yours,

/s/ Ernst & Young LLP

Ernst & Young LLP

Stock widget

Investing forum

SYNAGEVA BIOPHARMA CORP Reports